Nathan E Standifer

Affiliations

BioPharmaceuticals Research and Development, AstraZeneca, South San Francisco, California, USA.

Publications (2)

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.

Journal for immunotherapy of cancer

Avec: Sandip P Patel , Teresa Alonso-Gordoa , Susana Banerjee , Ding Wang , Jarushka Naidoo , Doug C Palmer , Lin-Yang Cheng , Panagiotis Kourtesis , Maria L Ascierto , Mayukh Das , Jennifer R Diamond , Matthew D Hellmann , Benedito A Carneiro

Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.

Cancer immunology, immunotherapy : CII

Avec: Elliot Naidus , Jerome Bouquet , David Y Oh , Timothy J Looney , Hai Yang , Lawrence Fong , Li Zhang

Réseau de co-auteurs

Sandip P Patel 1 collaboration

Teresa Alonso-Gordoa 1 collaboration

Susana Banerjee 1 collaboration

Ding Wang 1 collaboration

Jarushka Naidoo 1 collaboration

Doug C Palmer 1 collaboration

Lin-Yang Cheng 1 collaboration

Panagiotis Kourtesis 1 collaboration

Maria L Ascierto 1 collaboration

Mayukh Das 1 collaboration

Jennifer R Diamond 1 collaboration

Matthew D Hellmann 1 collaboration

Benedito A Carneiro 1 collaboration

Elliot Naidus 1 collaboration

Jerome Bouquet 1 collaboration

David Y Oh 1 collaboration

Timothy J Looney 1 collaboration

Hai Yang 1 collaboration

Lawrence Fong 1 collaboration

Li Zhang 1 collaboration